about
Functions of the adapter protein Cas: signal convergence and the determination of cellular responsesAntiestrogens, aromatase inhibitors, and apoptosis in breast cancerSynergistic promotion of c-Src activation and cell migration by Cas and AND-34/BCAR3.Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane rufflingIdentification of condition-specific regulatory modules through multi-level motif and mRNA expression analysis.BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells.Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b.Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis.ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer.Multilevel support vector regression analysis to identify condition-specific regulatory networksIdentifying cancer biomarkers by network-constrained support vector machines.NF-κB signaling is required for XBP1 (unspliced and spliced)-mediated effects on antiestrogen responsiveness and cell fate decisions in breast cancerInterferon regulatory factor-1 signaling regulates the switch between autophagy and apoptosis to determine breast cancer cell fateG-DOC: a systems medicine platform for personalized oncologyERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer.Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation.Nutritional modulation of the cell cycle and breast cancer.ERRβ splice variants differentially regulate cell cycle progression.Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response.Identifying protein interaction subnetworks by a bagging Markov random field-based method.Reconstruction of transcriptional regulatory networks by stability-based network component analysis.Trans-resveratrol boronic acid exhibits enhanced anti-proliferative activity on estrogen-dependent MCF-7 breast cancer cellsEndoplasmic reticulum stress, the unfolded protein response, and gene network modeling in antiestrogen resistant breast cancerGene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cellsThe role of X-box binding protein-1 in tumorigenicity.Antimitotic activity of DY131 and the estrogen-related receptor beta 2 (ERRβ2) splice variant in breast cancer.The proapoptotic molecule BLID interacts with Bcl-XL and its downregulation in breast cancer correlates with poor disease-free and overall survival.Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines.The A4396G polymorphism in interferon regulatory factor 1 is frequently expressed in breast cancer cell lines.interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant).Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.Differential prioritization of therapies to subtypes of triple negative breast cancer using a systems medicine method.The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer.Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma.Robust identification of transcriptional regulatory networks using a Gibbs sampler on outlier sum statistic
P50
Q24291815-A2E13E73-0381-4C62-8313-F9C3992ACC50Q28268250-9556CA92-72B7-4BCF-B181-E781CAF94DD2Q30310839-C98F0452-8420-4A8D-A593-70532E12795BQ30411760-3267606D-E459-4B83-B5D8-C475AD8EA2D3Q30417594-317501C3-FCCF-4C85-9045-F550CA441F34Q30432099-6CFE91B8-264A-4119-865A-67E0C04F7CADQ30441028-01E30CF3-74EB-403C-8598-1E7AD93F6E41Q33523022-C9C0F99D-F38A-4124-9AA6-B64393655622Q33836140-D7851881-2B40-49C7-843F-EF854B50F527Q33857304-82340398-58CF-4133-A69B-0B46E0C7551EQ34047245-60756619-E62B-4F69-B5D7-17161883D1ECQ34745409-81426190-8A17-41AE-8EF7-F0CA1D0AA36DQ35178371-218B7A69-E7B6-4915-93DE-FC4E8A35D5B0Q35238047-53933285-B87C-4539-91D8-994E2AFCB293Q35620279-EDD69AD3-3FBA-4B1E-B2E0-E19907253A0FQ35689023-8A7F2E02-46F7-4683-A8E8-37FC73CD35B6Q35990996-8255AF6A-0AE2-48D1-8A8A-5124061D6904Q36187539-FD49E0F7-6F23-4174-858C-D6488584C501Q36455407-ADD33A8B-8B44-4387-AE4F-C218F394DC61Q36559266-9B7C2717-7751-48EA-8CD4-0E65EE77B20AQ36840512-95E323A6-45BC-4CE0-A9FC-BC1C0AC1C031Q36919835-52521322-B722-4E92-B06C-805D97E612BBQ37072811-EBABB2AC-DC2D-4B73-9A05-20DBD6BAE42DQ37401741-145F820D-6659-4038-937D-F7AFBB50E791Q37553966-2A1043A8-B9A3-46A6-B5C5-2D717AB37315Q37565093-1229884B-58E7-473C-9480-81AD24182101Q39713570-ACC87423-8873-4EB6-A10C-30853586BD85Q40101179-30740DCE-9E98-464F-BB33-4BF11749F0FBQ40133661-6E2DD7DE-56B4-45FB-9067-4E946236463BQ40550091-2727A520-416C-4959-B072-92D093EF19A6Q46311036-0DA2C454-8DEC-49C0-8996-019719D69390Q47154705-F9FB9F2F-CDF1-4D30-AFF7-EF2A79FFA089Q52590861-2BDFB10E-1147-4FF8-86DD-2AEB4132FAECQ54935910-940A6A5B-A0AE-4EB0-B414-94C789C3EAF3Q57676341-B188065D-A9A8-4CF4-BEA4-2F155E0878B9
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Rebecca B Riggins
@ast
Rebecca B Riggins
@en
Rebecca B Riggins
@es
Rebecca B Riggins
@nl
type
label
Rebecca B Riggins
@ast
Rebecca B Riggins
@en
Rebecca B Riggins
@es
Rebecca B Riggins
@nl
prefLabel
Rebecca B Riggins
@ast
Rebecca B Riggins
@en
Rebecca B Riggins
@es
Rebecca B Riggins
@nl
P106
P21
P2456
P31
P496
0000-0002-1555-4431